The battle for compounded GLP1 continues
The battle for compounded GLP1s rages on -- powerful organizations with profit incentives continue to push for compounded GLP1s, with consumers caught in the middle.
Last year, Tirzepatide came off the the FDA shortage list and GLP1 compounders sued to continue compounding the massively popular drug. The fight is far from over, though the FDA has not turned back on the decision to remove the drug from the shortage list.
Instead what we have now is a situation in which the FDA has promised (via a related court filing) to not pursue legal action against compounders:
GLP1.Guide Staff
This is clearly not a sustainable position for the industry, and it's only a matter of time until legal action continues or other drugs (for example Semaglutide, the active ingredient in Ozempic and Mounjaro) come off the shortage list.
Compounders can only produce versions of drugs that are in shortage legally, and that's going to be a problem going forward.
So what's changed?
The rest of this article is no longer available for free – if you'd like to read the rest of our analysis, check us out on Substack:
